AU2020292278B2 - Sustained-release compositions of alpha-ketoglutarate - Google Patents

Sustained-release compositions of alpha-ketoglutarate

Info

Publication number
AU2020292278B2
AU2020292278B2 AU2020292278A AU2020292278A AU2020292278B2 AU 2020292278 B2 AU2020292278 B2 AU 2020292278B2 AU 2020292278 A AU2020292278 A AU 2020292278A AU 2020292278 A AU2020292278 A AU 2020292278A AU 2020292278 B2 AU2020292278 B2 AU 2020292278B2
Authority
AU
Australia
Prior art keywords
composition
ketoglutarate
release
calcium
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020292278A
Other languages
English (en)
Other versions
AU2020292278A1 (en
Inventor
Sumana Konar
David Eugene Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ponce De Leon Health Designated Activity Co
Original Assignee
Ponce De Leon Health Designated Activity Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ponce De Leon Health Designated Activity Co filed Critical Ponce De Leon Health Designated Activity Co
Publication of AU2020292278A1 publication Critical patent/AU2020292278A1/en
Application granted granted Critical
Publication of AU2020292278B2 publication Critical patent/AU2020292278B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2020292278A 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate Active AU2020292278B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US62/859,595 2019-06-10
US201962929024P 2019-10-31 2019-10-31
US62/929,024 2019-10-31
PCT/US2020/036987 WO2020252014A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Publications (2)

Publication Number Publication Date
AU2020292278A1 AU2020292278A1 (en) 2022-01-06
AU2020292278B2 true AU2020292278B2 (en) 2026-02-12

Family

ID=73781275

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020292278A Active AU2020292278B2 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Country Status (12)

Country Link
US (1) US20220265586A1 (enExample)
EP (1) EP3980001B1 (enExample)
JP (2) JP7751291B2 (enExample)
KR (1) KR20220044478A (enExample)
CN (1) CN114126601B (enExample)
AU (1) AU2020292278B2 (enExample)
BR (1) BR112021024952A2 (enExample)
DK (1) DK3980001T3 (enExample)
ES (1) ES3054304T3 (enExample)
IL (1) IL288782B2 (enExample)
TW (1) TWI869410B (enExample)
WO (1) WO2020252014A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112955139B (zh) * 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
MX2024008182A (es) * 2021-12-29 2024-09-24 Jrs Pharma Gmbh & Co Kg Lubricante para productos farmacéuticos y nutracéuticos.
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106246A1 (en) * 1998-05-28 2005-05-19 Byrd Edward A. Controlled release arginine alpha-ketoglutarate
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
WO2001039742A2 (en) 1999-12-03 2001-06-07 Polichem S.A. Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US7169755B2 (en) * 2000-12-20 2007-01-30 Alcon, Inc. Solution for removing cataracts via liquefracture
US20060029668A1 (en) 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
US20090005437A1 (en) * 2004-08-09 2009-01-01 Eyal Gottlieb Alpha-Ketoglutarates and Their Use as Therapeutic Agents
FR2967578B1 (fr) 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
US11331287B2 (en) * 2013-06-06 2022-05-17 Balchem Corporation Iron supplement
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN109432039B (zh) * 2015-06-03 2021-06-22 南京三迭纪医药科技有限公司 药品剂型及其使用
CN109803647A (zh) * 2016-09-30 2019-05-24 加州大学董事会 α-丁酮酸、α-酮戊二酸和2-羟基丁酸用于刺激毛发生长
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
MX2017004010A (es) * 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106246A1 (en) * 1998-05-28 2005-05-19 Byrd Edward A. Controlled release arginine alpha-ketoglutarate
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOGAN, J., "Hydroxypropylmethylcellulose sustained release technology", JOURNAL DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1989, vol. 15, no. 6, pages 975-999, DOI: 10.3109/03639048909043660 *

Also Published As

Publication number Publication date
JP2022537685A (ja) 2022-08-29
KR20220044478A (ko) 2022-04-08
US20220265586A1 (en) 2022-08-25
CA3142494A1 (en) 2020-12-17
JP7751291B2 (ja) 2025-10-08
TWI869410B (zh) 2025-01-11
TW202112362A (zh) 2021-04-01
EP3980001A1 (en) 2022-04-13
IL288782B1 (en) 2026-04-01
ES3054304T3 (en) 2026-02-02
JP2025124683A (ja) 2025-08-26
IL288782A (en) 2022-02-01
DK3980001T3 (da) 2025-12-01
WO2020252014A1 (en) 2020-12-17
EP3980001B1 (en) 2025-08-27
AU2020292278A1 (en) 2022-01-06
CN114126601A (zh) 2022-03-01
IL288782B2 (en) 2026-08-01
BR112021024952A2 (pt) 2022-02-15
CN114126601B (zh) 2025-07-15
EP3980001A4 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
US10688058B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP2025124683A (ja) アルファ－ケトグルタル酸塩の持続放出組成物
US20190201369A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
US9642808B2 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
AU2011222856A1 (en) Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
JP2017149725A (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
US20150030676A1 (en) Stablized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
US12178918B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
AU2020223515B2 (en) Afabicin formulation, method for making the same
SE1251371A1 (sv) Farmaceutiska kompositioner innefattande hydromorfon och naloxon
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
CA3142494C (en) Sustained-release compositions of alpha-ketoglutarate
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
HK40071632A (zh) α-酮戊二酸类化合物的持续释放组合物
HK40071632B (en) Sustained-release compositions of alpha-ketoglutarate
EP4023213A1 (en) Pharmaceutical compositions comprising alogliptin
EP2543363A1 (en) Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)